Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

PHASE3CompletedINTERVENTIONAL
Enrollment

971

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

January 8, 2019

Study Completion Date

January 8, 2019

Conditions
Insomnia Disorder
Interventions
DRUG

lemborexant

DRUG

Placebo

Trial Locations (114)

2169

Facility # 1, Quincy

2865

Facility # 1, Lincoln

11235

Facility # 1, Brooklyn

21075

Facility # 1, Elkridge

28601

Facility # 1, Hickory

32162

Facility # 1, The Villages

32256

Facility # 1, Jacksonville

32751

Facility # 1, Maitland

32765

Facility # 1, Oviedo

32801

Facility # 1, Orlando

33016

Facility # 1, Hialeah

33030

Facility # 1, Homestead

33161

Innovative Clinical Research Inc, Miami

33319

Facility # 1, Lauderhill

33634

Facility # 1, Tampa

33781

Facility # 1, Pinellas Park

34471

Facility # 1, Ocala

34747

Facility # 1, Celebration

38119

Facility # 1, Memphis

45417

Facility # 1, Dayton

47714

Facility # 1, Evansville

64114

Facility # 1, Kansas City

72758

Facility # 1, Rogers

73103

Facility # 2, Oklahoma City

73112

Facility # 1, Oklahoma City

76135

Facility # 1, Fort Worth

76904

Facility # 1, San Angelo

78705

Facility # 1, Austin

78731

Facility # 2, Austin

80909

Facility # 1, Colorado Springs

85224

Facility # 1, Chandler

Facility # 2, Chandler

87109

Facility # 1, Albuquerque

90048

Facility # 2, Los Angeles

90069

Facility # 1, Los Angeles

90210

Facility # 1, Beverly Hills

90404

Facility # 1, Santa Monica

90502

Facility # 1, Torrance

92374

Facility # 1, Redlands

95821

Facility # 1, Sacramento

97210

Facility # 1, Portland

98101

Facility # 1, Seattle

Unknown

Facility # 1, Kelowna

Facility # 1, Toronto

Facility # 1, Point-Claire

Facility # 1, Sherbrooke

Facility # 1, Oulu

Facility # 1, Helsinki

Facility # 1, Kuopio

Facility # 1, Tampere

Facility # 1, Turku

Facility # 2, Turku

Facility # 1, Bochum

Facility # 1, Leipzig

Facility # 1, Berlin

Facility # 2, Berlin

Facility # 3, Berlin

Facility # 1, Hamburg

Facility # 1, Hanover

Facility # 1, Milan

Facility # 1, Siena

Facility # 1, Roma

Eisai Trail Site 1, Maebashi

Eisai Trail Site 1, Sapporo

Eisai Trail Site 2, Sapporo

Eisai Trail Site 3, Sapporo

Eisai Trail Site 4, Sapporo

Eisai Trail Site 1, Sagamihara

Eisai Trial Site 1, Yokohama

Eisai Trial Site 2, Yokohama

Eisai Trial Site 3, Yokohama

Eisai Trail Site 1, Tokorozawa

Eisai Trail Site 1, Arakawa City

Eisai Trail Site 1, Katsushika-ku

Eisai Trail Site 1, Minato

Eisai Trail Site 2, Minato

Eisai Trail Site 1, Musashino

Eisai Trail Site 1, Ōta-ku

Eisai Trail Site 2, Ōta-ku

Eisai Trail Site 3, Ōta-ku

Eisai Trail Site 1, Shibuya City

Eisai Trail Site 1, Shinagawa

Eisai Trail Site 2, Shinagawa

Eisai Trail Site 1, Shinjuku

Eisai Trail Site 2, Shinjuku

Eisai Trail Site 1, Toshima City

Facility # 1, Monterrey

Facility # 1, Wellington

Facility # 1, Christchurch

Facility # 1, Dunedin

Facility # 1, Auckland

Facility # 1, Rotorua

Facility # 1, Tarnów

Facility # 1, Warsaw

Facility # 1, Gdansk

Facility # 1, Katowice

Facility # 1, Ostróda

Facility # 2, Warsaw

Facility # 3, Warsaw

Facility # 1, Brasov

Facility # 1, Bucharest

Facility # 1, Constanța

Facility # 1, Sibiu

Facility # 1, Târgu Mureş

Facility # 1, Seongnam-si

Facility # 1, Suwon

Facility # 1, Daegu

Facility # 1, Seoul

Facility # 3, Seoul

Facility # 1, Palma de Mallorca

Facility # 1, Torrejón de Ardoz

Facility # 1, Quart de Poblet

Facility # 1, Barcelona

Facility # 1, Valencia

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT02952820 - Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2) | Biotech Hunter | Biotech Hunter